XBiotech Competitors

XBiotech (NASDAQ:XBIT) and Revance Therapeutics (NASDAQ:RVNC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, risk, institutional ownership, earnings, dividends and analyst recommendations.

Earnings and Valuation

This table compares XBiotech and Revance Therapeutics' gross revenue, earnings per share (EPS) and valuation.

XBiotech has higher earnings, but lower revenue than Revance Therapeutics.

Volatility and Risk

XBiotech has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Revance Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500.

Insider and Institutional Ownership

14.8% of XBiotech shares are held by institutional investors. Comparatively, 74.4% of Revance Therapeutics shares are held by institutional investors. 31.0% of XBiotech shares are held by insiders. Comparatively, 4.8% of Revance Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares XBiotech and Revance Therapeutics' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings and target prices for XBiotech and Revance Therapeutics, as reported by MarketBeat.

Revance Therapeutics has a consensus target price of $37.75, suggesting a potential upside of 37.77%. Given Revance Therapeutics' higher probable upside, analysts clearly believe Revance Therapeutics is more favorable than XBiotech.

Summary

XBiotech beats Revance Therapeutics on 7 of the 11 factors compared between the two stocks.

XBiotech (NASDAQ:XBIT) and Axsome Therapeutics (NASDAQ:AXSM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings and recommmendations for XBiotech and Axsome Therapeutics, as reported by MarketBeat.

Axsome Therapeutics has a consensus target price of $152.6667, indicating a potential upside of 190.52%. Given Axsome Therapeutics' higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than XBiotech.

Risk and Volatility

XBiotech has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 2.59, meaning that its share price is 159% more volatile than the S&P 500.

Institutional and Insider Ownership

14.8% of XBiotech shares are held by institutional investors. Comparatively, 63.6% of Axsome Therapeutics shares are held by institutional investors. 31.0% of XBiotech shares are held by insiders. Comparatively, 26.0% of Axsome Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares XBiotech and Axsome Therapeutics' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares XBiotech and Axsome Therapeutics' top-line revenue, earnings per share and valuation.

Summary

XBiotech beats Axsome Therapeutics on 5 of the 9 factors compared between the two stocks.

FibroGen (NASDAQ:FGEN) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of current recommendations and price targets for FibroGen and XBiotech, as reported by MarketBeat.

FibroGen currently has a consensus target price of $45.8333, indicating a potential upside of 128.25%. Given FibroGen's higher possible upside, equities research analysts clearly believe FibroGen is more favorable than XBiotech.

Institutional and Insider Ownership

75.1% of FibroGen shares are owned by institutional investors. Comparatively, 14.8% of XBiotech shares are owned by institutional investors. 3.4% of FibroGen shares are owned by company insiders. Comparatively, 31.0% of XBiotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares FibroGen and XBiotech's revenue, earnings per share (EPS) and valuation.

XBiotech has lower revenue, but higher earnings than FibroGen.

Profitability

This table compares FibroGen and XBiotech's net margins, return on equity and return on assets.

Risk and Volatility

FibroGen has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

Summary

XBiotech beats FibroGen on 6 of the 11 factors compared between the two stocks.

IGM Biosciences (NASDAQ:IGMS) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, profitability and analyst recommendations.

Volatility & Risk

IGM Biosciences has a beta of -1.12, suggesting that its share price is 212% less volatile than the S&P 500. Comparatively, XBiotech has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for IGM Biosciences and XBiotech, as reported by MarketBeat.com.

IGM Biosciences currently has a consensus price target of $98.8750, suggesting a potential upside of 70.65%. Given IGM Biosciences' higher probable upside, analysts plainly believe IGM Biosciences is more favorable than XBiotech.

Profitability

This table compares IGM Biosciences and XBiotech's net margins, return on equity and return on assets.

Institutional & Insider Ownership

47.6% of IGM Biosciences shares are owned by institutional investors. Comparatively, 14.8% of XBiotech shares are owned by institutional investors. 79.3% of IGM Biosciences shares are owned by insiders. Comparatively, 31.0% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares IGM Biosciences and XBiotech's revenue, earnings per share and valuation.

Summary

XBiotech beats IGM Biosciences on 5 of the 9 factors compared between the two stocks.

XBiotech (NASDAQ:XBIT) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and price targets for XBiotech and Kura Oncology, as reported by MarketBeat.

Kura Oncology has a consensus price target of $39.5455, indicating a potential upside of 43.07%. Given Kura Oncology's higher possible upside, analysts clearly believe Kura Oncology is more favorable than XBiotech.

Earnings & Valuation

This table compares XBiotech and Kura Oncology's top-line revenue, earnings per share and valuation.

Volatility & Risk

XBiotech has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, meaning that its stock price is 115% more volatile than the S&P 500.

Institutional and Insider Ownership

14.8% of XBiotech shares are owned by institutional investors. Comparatively, 94.7% of Kura Oncology shares are owned by institutional investors. 31.0% of XBiotech shares are owned by insiders. Comparatively, 11.0% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares XBiotech and Kura Oncology's net margins, return on equity and return on assets.

Summary

XBiotech beats Kura Oncology on 5 of the 9 factors compared between the two stocks.

XBiotech (NASDAQ:XBIT) and Cytokinetics (NASDAQ:CYTK) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Profitability

This table compares XBiotech and Cytokinetics' net margins, return on equity and return on assets.

Volatility and Risk

XBiotech has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.

Institutional & Insider Ownership

14.8% of XBiotech shares are owned by institutional investors. Comparatively, 97.1% of Cytokinetics shares are owned by institutional investors. 31.0% of XBiotech shares are owned by insiders. Comparatively, 6.4% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares XBiotech and Cytokinetics' gross revenue, earnings per share and valuation.

XBiotech has higher earnings, but lower revenue than Cytokinetics.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for XBiotech and Cytokinetics, as provided by MarketBeat.

Cytokinetics has a consensus target price of $34.6364, suggesting a potential upside of 37.77%. Given Cytokinetics' higher probable upside, analysts plainly believe Cytokinetics is more favorable than XBiotech.

Summary

XBiotech beats Cytokinetics on 7 of the 11 factors compared between the two stocks.